ArticleJournal of hepatocellular carcinoma2026
Prognostic Factors Analysis in Patients with Hepatocellular Carcinoma Receiving PD-1/PD-L1 Inhibitors.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced hepatocellular carcinoma (HCC); however, only a minority of patients derive benefits, and reliable biomarkers remain lacking. This study aimed to investigate the associations between peripheral blood markers, clinical characteristics, and outcomes in patients receiving programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors. Methods: Clinical and laboratory data from 101 patients treated with PD‑1/PD‑L1 inhibitors were retrospectively analyzed. Optimal cutoff values for continuous variables were determined using the X‑tile. Intergroup comparisons were performed using Pearson's chi-squared or Fisher's exact tests. Univariate Cox regression (SPSS 26.0) was used to identify potential prognostic factors (P<0.1), which were further evaluated by Log rank test and Kaplan-Meier curves. Independent prognostic factors were determined using a multivariate Cox regression analysis. Results: The factors associated with efficacy included body mass index, Child‑Pugh class, line of treatment, distant metastasis, bone metastasis, alkaline phosphatase, and total bilirubin. Prognosis‑related indicators included lung metastasis, hemoglobin, absolute neutrophil count, alkaline phosphatase, gamma‑glutamyl transferase, C‑reactive protein, and the best response. Conclusion: Based on routine clinical and hematological data, this prognostic study provides an accessible tool for personalized immunotherapy management of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.